<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02386735</url>
  </required_header>
  <id_info>
    <org_study_id>KSBL2015-017</org_study_id>
    <nct_id>NCT02386735</nct_id>
  </id_info>
  <brief_title>Reduction of Corticosteroid Use in Outpatient Treatment of Exacerbated COPD</brief_title>
  <acronym>RECUT</acronym>
  <official_title>Reduction of Corticosteroid Use in Outpatient Treatment of Exacerbated COPD - a Randomized, Double-blind, Non-inferiority Study (The &quot;RECUT&quot;-Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. Jörg Leuppi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut für Hausarztmedizin Basel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kantonsspital Baselland Bruderholz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cantonal Hosptal, Baselland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background

      Chronic obstructive pulmonary disease (COPD) is a major public health issue with no curative
      treatment. In Switzerland estimated 5-7% of the total population are suffering from this
      chronic disease. According to current guidelines corticosteroids are part of treatment of
      acute exacerbations in COPD patients. Several studies suggest that corticosteroids accelerate
      the recovery of forced expiratory volume in 1 second (FEV1), decrease duration of
      hospitalization, reduce treatment failure rate and improve clinical outcome. The additional
      therapeutic benefit on FEV1-recovery tough seems only to last for three to five days. The
      investigators recently published a hospital-based study showing that in patients presenting
      to emergency departments with acute exacerbation of COPD, a short five day treatment with
      systemic steroids was not inferior to a conventional 14 day treatment with regard to
      re-exacerbation. Cumulative corticosteroid dose could be reduced in this trial. To the
      investigators knowledge no data is available about the minimal necessary corticosteroid dose
      in an outpatient treatment setting so far.

      Aim

      The primary aim of this study is to investigate in an outpatient setting, whether a three day
      treatment with orally administered systemic corticosteroids is non-inferior to a five day
      treatment in acute exacerbation of COPD and if total glucocorticoid exposure can be reduced
      by shorter therapy.

      Hypothesis

      The investigators postulate, that in an outpatient setting, where generally less severe
      exacerbations are being treated, a three day treatment duration of systemic corticosteroids
      should be non-inferior to a five day treatment duration with regard to treatment benefits but
      decrease cumulative corticosteroid exposure.

      Design and Setting

      This study is going to be performed as a prospective, randomized, double-blind,
      placebo-controlled, non-inferiority trial in an outpatient setting. Randomization will be
      performed as block randomization with a 1:1 allocation. The investigators are going to
      recruit GPs in northwestern and central Switzerland.

      Methods

      The investigators are going to include patients presenting to GP's with acute exacerbation of
      COPD. When matching the investigators eligibility criteria and written informed consent is
      given, patients included in the study are receiving systemic corticosteroid treatment
      (equivalent of 40mg prednisone daily) for either five days (conventional arm) or three days
      (interventional arm) followed by two days of placebo for the interventional group.
      Pre-randomized, identically looking, numbered blisters are given to all patients included in
      the study. Antibiotic treatment (Amoxicillin/Clavulanic acid, 625mg 3/d, for ten days) is
      given to all patients with a CRP ≥50mg/l, COPD and known diagnosis of bronchiectasis, as well
      as patients presenting with all three of the following symptoms: change of baseline dyspnea,
      change of sputum quantity and sputum purulence. Further initial treatment and steroid
      treatment after inclusion is determined and documented by the GP. Patients will undergo
      follow-up visits at day three and seven by their GP as well as follow-up phone calls executed
      by the study center at day 30, 90 and 180.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to next exacerbation</measure>
    <time_frame>Six month follow-up period after index exacerbation.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative glucocorticoid dose</measure>
    <time_frame>Six month follow-up period after index exacerbation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucocorticoid side effects and complications</measure>
    <time_frame>Six month follow-up period after index exacerbation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FEV1</measure>
    <time_frame>7 days follow-up period after index exacerbation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization rate during index exacerbation</measure>
    <time_frame>Six month follow-up period after index exacerbation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall mortality</measure>
    <time_frame>Six month follow-up period after index exacerbation.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">470</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <condition>Adverse Effect of Glucocorticoids and Synthetic Analogues</condition>
  <condition>Disease Exacerbation</condition>
  <arm_group>
    <arm_group_label>Investigational treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients included in the placebo group are receiving systemic corticosteroid treatment (equivalent of 40mg prednisone daily) for three days followed by two days of placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients included in the control group are receiving systemic corticosteroid treatment (equivalent of 40mg prednisone daily) for five days as recommended in current guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Three days prednisone 40mg, two days placebo</description>
    <arm_group_label>Investigational treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Five days prednisone 40mg.</description>
    <arm_group_label>Standard treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed Consent as documented by signature

          -  Age ≥40 years

          -  History of ≥10 pack-years of smoking (past or present smokers)

          -  Airway obstruction, defined as FEV1/FVC≤70%

          -  Current acute exacerbation of COPD by clinical criteria, defined by the presence of at
             least two of the following:

               -  Change of baseline dyspnea

               -  Change of cough

               -  Change of sputum quantity or purulence

        Exclusion Criteria:

          -  Diagnosis of asthma

          -  Initial necessity of hospitalization

          -  Women who are pregnant or breast feeding

          -  Premenopausal women with insufficient contraception and anamnestic risk for pregnancy

          -  Severe coexisting disease with life expectancy &lt;6 months

          -  Diagnosis of tuberculosis

          -  Known severe immunosuppression or immunosuppression after solid organ or stem cell
             transplantation

          -  Inability to follow study procedures, e.g. due to language problems, psychological
             disorders, dementia, etc. of the participant

          -  Participation in another study involving an investigational drug

          -  Previous enrolment into the current study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joerg Leuppi, Prof. Dr. med.</last_name>
    <phone>+41 61 925 21 80</phone>
    <email>joerg.leuppi@ksbl.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kantonsspital Baselland</name>
      <address>
        <city>Liestal</city>
        <state>BL</state>
        <zip>4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joerg Leuppi, Prof. Dr. med.</last_name>
      <phone>+41 61 925 21 80</phone>
      <email>joerg.leuppi@ksbl.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.goldcopd.org</url>
    <description>8. The Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2014</description>
  </link>
  <reference>
    <citation>Leuppi JD, Miedinger D, Chhajed PN, Buess C, Schafroth S, Bucher HC, Tamm M. Quality of spirometry in primary care for case finding of airway obstruction in smokers. Respiration. 2010;79(6):469-74. doi: 10.1159/000243162. Epub 2009 Sep 26.</citation>
    <PMID>19786731</PMID>
  </reference>
  <reference>
    <citation>Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002 Oct;57(10):847-52. Erratum in: Thorax. 2008 Aug;63(8):753.</citation>
    <PMID>12324669</PMID>
  </reference>
  <reference>
    <citation>Makris D, Moschandreas J, Damianaki A, Ntaoukakis E, Siafakas NM, Milic Emili J, Tzanakis N. Exacerbations and lung function decline in COPD: new insights in current and ex-smokers. Respir Med. 2007 Jun;101(6):1305-12. Epub 2006 Nov 16.</citation>
    <PMID>17112715</PMID>
  </reference>
  <reference>
    <citation>Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med. 2000 Jul 27;343(4):269-80. Review.</citation>
    <PMID>10911010</PMID>
  </reference>
  <reference>
    <citation>Sapey E, Stockley RA. COPD exacerbations . 2: aetiology. Thorax. 2006 Mar;61(3):250-8. Review.</citation>
    <PMID>16517585</PMID>
  </reference>
  <reference>
    <citation>Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008 Nov 27;359(22):2355-65. doi: 10.1056/NEJMra0800353. Review.</citation>
    <PMID>19038881</PMID>
  </reference>
  <reference>
    <citation>Mohan A, Chandra S, Agarwal D, Guleria R, Broor S, Gaur B, Pandey RM. Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: a systematic review. Respirology. 2010 Apr;15(3):536-42. doi: 10.1111/j.1440-1843.2010.01722.x. Review. Erratum in: Respirology. 2010 Jul,15(5):871.</citation>
    <PMID>20415983</PMID>
  </reference>
  <reference>
    <citation>Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, Duerring U, Henzen C, Leibbrandt Y, Maier S, Miedinger D, Müller B, Scherr A, Schindler C, Stoeckli R, Viatte S, von Garnier C, Tamm M, Rutishauser J. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013 Jun 5;309(21):2223-31. doi: 10.1001/jama.2013.5023.</citation>
    <PMID>23695200</PMID>
  </reference>
  <reference>
    <citation>Albert RK, Martin TR, Lewis SW. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med. 1980 Jun;92(6):753-8.</citation>
    <PMID>6770731</PMID>
  </reference>
  <reference>
    <citation>Emerman CL, Connors AF, Lukens TW, May ME, Effron D. A randomized controlled trial of methylprednisolone in the emergency treatment of acute exacerbations of COPD. Chest. 1989 Mar;95(3):563-7.</citation>
    <PMID>2920584</PMID>
  </reference>
  <reference>
    <citation>Bullard MJ, Liaw SJ, Tsai YH, Min HP. Early corticosteroid use in acute exacerbations of chronic airflow obstruction. Am J Emerg Med. 1996 Mar;14(2):139-43.</citation>
    <PMID>8924134</PMID>
  </reference>
  <reference>
    <citation>Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med. 1996 Aug;154(2 Pt 1):407-12.</citation>
    <PMID>8756814</PMID>
  </reference>
  <reference>
    <citation>Aaron SD, Vandemheen KL, Hebert P, Dales R, Stiell IG, Ahuja J, Dickinson G, Brison R, Rowe BH, Dreyer J, Yetisir E, Cass D, Wells G. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med. 2003 Jun 26;348(26):2618-25.</citation>
    <PMID>12826636</PMID>
  </reference>
  <reference>
    <citation>Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 1999 Jun 24;340(25):1941-7.</citation>
    <PMID>10379017</PMID>
  </reference>
  <reference>
    <citation>Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet. 1999 Aug 7;354(9177):456-60.</citation>
    <PMID>10465169</PMID>
  </reference>
  <reference>
    <citation>Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest. 2003 Aug;124(2):459-67.</citation>
    <PMID>12907529</PMID>
  </reference>
  <reference>
    <citation>Miravitlles M, Mayordomo C, Artés M, Sánchez-Agudo L, Nicolau F, Segú JL. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group. Estudio Observacional de la Limitación Obstructiva al Flujo aEreo. Respir Med. 1999 Mar;93(3):173-9.</citation>
    <PMID>10464874</PMID>
  </reference>
  <reference>
    <citation>Walsh LJ, Lewis SA, Wong CA, Cooper S, Oborne J, Cawte SA, Harrison T, Green DJ, Pringle M, Hubbard R, Tattersfield AE. The impact of oral corticosteroid use on bone mineral density and vertebral fracture. Am J Respir Crit Care Med. 2002 Sep 1;166(5):691-5.</citation>
    <PMID>12204867</PMID>
  </reference>
  <reference>
    <citation>Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med. 1994 Jul;150(1):11-6.</citation>
    <PMID>8025735</PMID>
  </reference>
  <reference>
    <citation>Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, Towse L, Finnigan H, Dahl R, Decramer M, Chanez P, Wouters EF, Calverley PM; WISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014 Oct 2;371(14):1285-94. doi: 10.1056/NEJMoa1407154. Epub 2014 Sep 8.</citation>
    <PMID>25196117</PMID>
  </reference>
  <reference>
    <citation>Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E; BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007 Sep 1;370(9589):741-50. Erratum in: Lancet. 2012 Sep 1;380(9844):806.</citation>
    <PMID>17765523</PMID>
  </reference>
  <reference>
    <citation>Jochmann A, Scherr A, Jochmann DC, Miedinger D, Török SS, Chhajed PN, Tamm M, Leuppi JD. Impact of adherence to the GOLD guidelines on symptom prevalence, lung function decline and exacerbation rate in the Swiss COPD cohort. Swiss Med Wkly. 2012 Apr 5;142:w13567. doi: 10.4414/smw.2012.13567.</citation>
    <PMID>22481636</PMID>
  </reference>
  <reference>
    <citation>Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987 Feb;106(2):196-204.</citation>
    <PMID>3492164</PMID>
  </reference>
  <reference>
    <citation>Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000 May;117(5 Suppl 2):398S-401S. Review.</citation>
    <PMID>10843984</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2015</study_first_submitted>
  <study_first_submitted_qc>March 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2015</study_first_posted>
  <last_update_submitted>August 4, 2017</last_update_submitted>
  <last_update_submitted_qc>August 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cantonal Hosptal, Baselland</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Jörg Leuppi</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Corticosteroid treatment</keyword>
  <keyword>COPD</keyword>
  <keyword>Primary Health Care</keyword>
  <keyword>Randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

